Literature DB >> 20820869

The detection of CMV pp65 and IE1 in glioblastoma multiforme.

Kenneth G Lucas1, Lei Bao, Richard Bruggeman, Kimberly Dunham, Charles Specht.   

Abstract

Glioblastoma multiforme (GBM) is a highly lethal brain tumor affecting children and adults, with the majority of affected individuals dying from their disease by 2 years following diagnosis. Other groups have reported the association of cytomegalovirus (CMV) with GBM, and we sought to confirm these findings in a large series of patients with primary GBM from our institution. Immunohistochemical analysis of paraffin embedded tissue sections was performed on 49 newly diagnosed GBM tumors, the largest series reported to date. We confirmed the presence of CMV pp65 on 25/49 (51%) and of IE1 on 8/49 (16%) of these tumors. While pp65 and IE1 are generally found in the nucleus of cells that are permissibly infected by CMV, GBM in this series had mostly cytoplasmic staining, with only 16% having nuclear staining for one or both of these antigens. We infected GBM cell lines with a laboratory strain of CMV, and found that most of the staining was cytoplasmic, with some perinuclear localization of IE1. To test the potential for CMV infected GBM cells to be recognized by CMV pp65 and IE1 specific cytotoxic T lymphocytes (CTL), we used CMV infected GBM cell lines in cytotoxicity assays with human leukocyte antigen partially matched CMV CTL. Lysis of CMV infected GBM tumor cells was accentuated by pre-treating these cell lines with either the demethylating agent decitabine or interferon-γ, both of which were shown to increase MHC Class I and II expression on tumor cells in vitro. These studies confirm the presence of CMV pp65 or IE1 on approximately half of GBM, with the possibility that CMV positive tumor cells can be recognized by CMV pp65/IE1 specific T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20820869     DOI: 10.1007/s11060-010-0383-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  47 in total

1.  Identification of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other.

Authors:  E A Fortunato; M H Sommer; K Yoder; D H Spector
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 2.  Viral strategies of immune evasion.

Authors:  H L Ploegh
Journal:  Science       Date:  1998-04-10       Impact factor: 47.728

3.  Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups.

Authors:  F G Davis; V Kupelian; S Freels; B McCarthy; T Surawicz
Journal:  Neuro Oncol       Date:  2001-07       Impact factor: 12.300

4.  Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

Authors:  J S Yu; C J Wheeler; P M Zeltzer; H Ying; D N Finger; P K Lee; W H Yong; F Incardona; R C Thompson; M S Riedinger; W Zhang; R M Prins; K L Black
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

5.  Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.

Authors:  Isaac Yang; Thomas J Kremen; Adrian J Giovannone; Elena Paik; Sylvia K Odesa; Robert M Prins; Linda M Liau
Journal:  J Neurosurg       Date:  2004-02       Impact factor: 5.115

6.  Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer.

Authors:  Lualhati Harkins; Andrea L Volk; Minu Samanta; Ivan Mikolaenko; William J Britt; Kirby I Bland; Charles S Cobbs
Journal:  Lancet       Date:  2002-11-16       Impact factor: 79.321

Review 7.  Simian virus 40 and its association with human lymphomas.

Authors:  Regis A Vilchez; Janet S Butel
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

8.  Long-term infection and shedding of human cytomegalovirus in T98G glioblastoma cells.

Authors:  Min Hua Luo; Elizabeth A Fortunato
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

9.  In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.

Authors:  William Y Ho; Hieu N Nguyen; Matthias Wolfl; Juergen Kuball; Philip D Greenberg
Journal:  J Immunol Methods       Date:  2006-01-26       Impact factor: 2.303

10.  Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein.

Authors:  C Hagemeier; R Caswell; G Hayhurst; J Sinclair; T Kouzarides
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

View more
  66 in total

1.  Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.

Authors:  Alexia Ghazi; Aidin Ashoori; Patrick J Hanley; Vita S Brawley; Donald R Shaffer; Yvonne Kew; Suzanne Z Powell; Robert Grossman; Zakaria Grada; Michael E Scheurer; Meenakshi Hegde; Ann M Leen; Catherine M Bollard; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk; Nabil Ahmed
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

2.  Consensus on the role of human cytomegalovirus in glioblastoma.

Authors:  Kristine Dziurzynski; Susan M Chang; Amy B Heimberger; Robert F Kalejta; Stuart R McGregor Dallas; Martine Smit; Liliana Soroceanu; Charles S Cobbs
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

3.  Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.

Authors:  Afsar Rahbar; Madeleine Cederarv; Nina Wolmer-Solberg; Charlotte Tammik; Giuseppe Stragliotto; Inti Peredo; Olesja Fornara; Xinling Xu; Mensur Dzabic; Chato Taher; Petra Skarman; Cecilia Söderberg-Nauclér
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

Review 4.  Glioblastoma antigen discovery--foundations for immunotherapy.

Authors:  Tej D Azad; Seyed-Mostafa Razavi; Benjamin Jin; Karen Lee; Gordon Li
Journal:  J Neurooncol       Date:  2015-06-05       Impact factor: 4.130

Review 5.  The roles of viruses in brain tumor initiation and oncomodulation.

Authors:  Alexander Kofman; Lucasz Marcinkiewicz; Evan Dupart; Anton Lyshchev; Boris Martynov; Anatolii Ryndin; Elena Kotelevskaya; Jay Brown; David Schiff; Roger Abounader
Journal:  J Neurooncol       Date:  2011-07-01       Impact factor: 4.130

Review 6.  Cell-based immunotherapy against gliomas: from bench to bedside.

Authors:  M Sarah S Bovenberg; M Hannah Degeling; Bakhos A Tannous
Journal:  Mol Ther       Date:  2013-05-07       Impact factor: 11.454

Review 7.  The Safety of available immunotherapy for the treatment of glioblastoma.

Authors:  S Harrison Farber; Aladine A Elsamadicy; Ahmet Fatih Atik; Carter M Suryadevara; Pakawat Chongsathidkiet; Peter E Fecci; John H Sampson
Journal:  Expert Opin Drug Saf       Date:  2017-01-03       Impact factor: 4.250

Review 8.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

9.  Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.

Authors:  Smita K Nair; Gabriel De Leon; David Boczkowski; Robert Schmittling; Weihua Xie; Janet Staats; Rebecca Liu; Laura A Johnson; Kent Weinhold; Gary E Archer; John H Sampson; Duane A Mitchell
Journal:  Clin Cancer Res       Date:  2014-03-21       Impact factor: 12.531

10.  Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.

Authors:  Corey Smith; Katie E Lineburg; J Paulo Martins; George R Ambalathingal; Michelle A Neller; Beth Morrison; Katherine K Matthews; Sweera Rehan; Pauline Crooks; Archana Panikkar; Leone Beagley; Laetitia Le Texier; Sriganesh Srihari; David Walker; Rajiv Khanna
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.